Sarcopenia, characterized by reduced muscle mass, decreased strength, and impaired function, can lead to adverse outcomes, such as frailty, falls, fractures and disability, and subsequently lead to decreased quality of life, increased risk of complications and mortality and elevated healthcare costs. With the accelerating process of global aging, the prevalence of sarcopenia has significantly risen, posing a major public health threat and socioeconomic burden to populations worldwide. To more effectively implement medical nutrition management and exercise intervention for patients with sarcopenia, the Chinese Clinical Nutritionist Center of Chinese Medical Doctor Association and the Nutrition Oncology Branch and Geriatric Nutrition Branch of the Chinese Nutrition Society, in collaboration with the Nutrition and Food Safety Branch of Chinese Geriatrics Society, have developed the Expert Consensus on Medical Nutrition Management and Exercise Intervention for Sarcopenia (2024) based on the latest research evidence, clinical practice experiences and clinical nutrition guidelines. This consensus serves as a reference for clinical diagnosis and treatment of sarcopenia. The consensus emphasizes that the diagnosis and treatment of sarcopenia should focus on elderly population and also encompass patients with related chronic diseases including diabetes, inflammatory bowel disease, cancer, cognitive dysfunction and Parkinson's disease. Multi-modal lifestyle interventions centered on nutrition and exercise remain the preferred strategy for the prevention and treatment of sarcopenia.

Sarcopenia, characterized by reduced muscle mass, decreased strength, and impaired function, can lead to adverse outcomes, such as frailty, falls, fractures and disability, and subsequently lead to decreased quality of life, increased risk of complications and mortality and elevated healthcare costs. With the accelerating process of global aging, the prevalence of sarcopenia has significantly risen, posing a major public health threat and socioeconomic burden to populations worldwide. To more effectively implement medical nutrition management and exercise intervention for patients with sarcopenia, the Chinese Clinical Nutritionist Center of Chinese Medical Doctor Association and the Nutrition Oncology Branch and Geriatric Nutrition Branch of the Chinese Nutrition Society, in collaboration with the Nutrition and Food Safety Branch of Chinese Geriatrics Society, have developed the Expert Consensus on Medical Nutrition Management and Exercise Intervention for Sarcopenia (2024) based on the latest research evidence, clinical practice experiences and clinical nutrition guidelines. This consensus serves as a reference for clinical diagnosis and treatment of sarcopenia. The consensus emphasizes that the diagnosis and treatment of sarcopenia should focus on elderly population and also encompass patients with related chronic diseases including diabetes, inflammatory bowel disease, cancer, cognitive dysfunction and Parkinson's disease. Multi-modal lifestyle interventions centered on nutrition and exercise remain the preferred strategy for the prevention and treatment of sarcopenia.

Objective: To investigate the effects of the cooperative actions of isoflavone, vitamin C and E on the expression of acute C reactive protein (CRP) and interleukin 6 (IL-6) in the patients with typeⅡdiabetic mellitus (DM). Method: Ninety six patients with DM were divided randomly into 4 groups, DM control group(B), and groups receiving low(C), medium (D) , and high (E) dose of the compound antioxidant of isoflavone, vitamin C and E respectively. Another 24 healthy subjects served as normal control group (A). Observe the changes of the levels of CRP and IL-6 during oral glucose tolerance test (OGTT). Results: The peak of serum levels of CRP and IL-6 in the patients of DM control group and lower dosage group appeared 1 h after OGTT and were significantly higher than the 0 h value (P

Objective: To observe the co-effect of antioxidant compound, soybean isoflavone (SI), VC and VE on glucose and insulin response after oral glucose load in Type 2 Diabetes Mellitus (T2DM) . Methods: 96 selected T2DM patients (50% male, 50% female) were randomly divided into 4 groups according to the dosage of the compound given , none (group B), low dosage (group C), medium dosage (group D) and high dosage (group E) . The normal control (group A) included 24 persons half male, half female . Blood glucose and insulin were determined at OGTT 0 h, 1 h, 2 h, 4 h, 6 h, and the areas under the curve (AUC) of blood insulin/glucose were calculated. Results: The AUC of blood insulin/glucose of male was higher than female in control group, but both were lower than those of four diabetes groups. In both genders of the diabetes groups, blood insulin AUC of group C, D, E was lower than group B, blood glucose AUC of group D, E was lower than group C and B. There was significant difference in blood insulin and glucose AUC of group E as compared to group B in female (P